Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.
glioma
glioma cell evasion
immune checkpoints
immune microenvironment
immunotherapy
therapy resistance
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
12
2022
accepted:
04
05
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, which makes immunotherapy the subject of active research at present. The anti-tumor immune response could also be considered a prognostic factor since each stage of cancer development is regulated by immune cells. However, glioma microenvironment contains malignant cells that secrete numerous chemokines, cytokines and growth factors, promoting the infiltration of immunosuppressive cells into the tumor, which limit the functioning of the immune system against glioma cells. Recently, researchers have been able to reverse the immune resistance of cancer cells and thus activate the anti-tumor immune response through different immunotherapy strategies. Here, we review the general concept of glioma's immune microenvironment and report the impact of its distinct components on the anti-tumor immune response. We also discuss the mechanisms of glioma cell evasion from the immune response and pinpoint some potential therapeutic pathways, which could alleviate such resistance.
Identifiants
pubmed: 37274252
doi: 10.3389/fonc.2023.1135430
pmc: PMC10235598
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1135430Informations de copyright
Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Exp Med. 2021 Jan 4;218(1):
pubmed: 32991668
Int J Cancer. 2019 Nov 1;145(9):2535-2546
pubmed: 31241175
PLoS One. 2017 Jan 20;12(1):e0169932
pubmed: 28107450
BMC Immunol. 2009 Feb 18;10:11
pubmed: 19226468
J Leukoc Biol. 2019 Feb;105(2):243-255
pubmed: 30387907
Front Immunol. 2021 Jul 09;12:679425
pubmed: 34305910
Mutat Res. 2005 Jan 6;569(1-2):87-100
pubmed: 15603754
Biomed Pharmacother. 2020 Jan;121:109610
pubmed: 31710894
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cell Stem Cell. 2014 Mar 6;14(3):357-69
pubmed: 24607407
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Br J Cancer. 2014 May 13;110(10):2560-8
pubmed: 24691423
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
Nat Immunol. 2019 Sep;20(9):1100-1109
pubmed: 31358997
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
Oncoimmunology. 2018 Jan 16;7(4):e1412909
pubmed: 29632728
Neuro Oncol. 2010 Apr;12(4):351-65
pubmed: 20308313
Mol Cancer Ther. 2010 Jan;9(1):67-78
pubmed: 20053772
Int J Biochem Cell Biol. 2014 Dec;57:63-8
pubmed: 25450457
Nat Rev Immunol. 2007 Sep;7(9):737-44
pubmed: 17673918
Int J Mol Sci. 2023 Apr 03;24(7):
pubmed: 37047660
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
Hum Vaccin Immunother. 2018 Feb 1;14(2):255-268
pubmed: 29087782
Neuro Oncol. 2016 Oct;18(10):1402-12
pubmed: 27116977
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Int J Clin Exp Med. 2015 Feb 15;8(2):1792-802
pubmed: 25932107
Sci Transl Med. 2016 Mar 2;8(328):328ra27
pubmed: 26936504
Immunol Rev. 2006 Dec;214:229-38
pubmed: 17100888
JCI Insight. 2018 May 17;3(10):
pubmed: 29769444
J Neuropathol Exp Neurol. 2015 May;74(5):390-400
pubmed: 25853692
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Mol Med Rep. 2014 Jul;10(1):411-6
pubmed: 24737504
Trends Cancer. 2019 Jul;5(7):393-396
pubmed: 31311653
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
Cancers (Basel). 2019 Mar 06;11(3):
pubmed: 30845654
J Control Release. 2020 Apr 10;320:63-72
pubmed: 31917294
Mol Ther. 2018 Apr 4;26(4):986-995
pubmed: 29503195
World Neurosurg. 2017 Jul;103:538-549
pubmed: 28427971
Adv Exp Med Biol. 2018;995:1-41
pubmed: 30539504
Front Oncol. 2021 Feb 02;10:608609
pubmed: 33604291
Nat Cancer. 2021 Jun;2(6):584-586
pubmed: 35121939
Cancer Cell Int. 2019 Oct 11;19:265
pubmed: 31632199
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Br J Cancer. 2003 Oct 6;89(7):1172-9
pubmed: 14520441
Clin Cancer Res. 2013 Jun 15;19(12):3165-75
pubmed: 23613317
Cells. 2019 Jan 31;8(2):
pubmed: 30708988
Int J Cancer. 2017 Nov 15;141(10):2082-2092
pubmed: 28758198
Neurol Sci. 2017 Sep;38(9):1571-1577
pubmed: 28593528
J Neuroinflammation. 2019 Jul 12;16(1):146
pubmed: 31300060
Asian Pac J Cancer Prev. 2013;14(1):309-14
pubmed: 23534743
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674721
Sci Rep. 2019 Oct 10;9(1):14643
pubmed: 31601888
Oncotarget. 2018 Apr 20;9(30):21569-21579
pubmed: 29765561
Neuro Oncol. 2011 Jun;13(6):591-9
pubmed: 21636707
Front Surg. 2016 Mar 02;3:11
pubmed: 26973839
Nat Rev Immunol. 2022 Aug;22(8):513-524
pubmed: 34903877
PLoS One. 2011 Jan 20;6(1):e16195
pubmed: 21283755
Int J Mol Sci. 2018 Sep 22;19(10):
pubmed: 30248992
Theranostics. 2019 Jul 9;9(18):5347-5358
pubmed: 31410219
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991681
Blood. 2014 Aug 28;124(9):1450-9
pubmed: 25037628
Brain Res. 2015 Aug 18;1617:18-27
pubmed: 25110235
J Immunol. 2004 Jan 1;172(1):104-13
pubmed: 14688315
Oncol Lett. 2016 Mar;11(3):1829-1834
pubmed: 26998085
Expert Opin Biol Ther. 2014 Oct;14(10):1411-25
pubmed: 24934899
Proc (Bayl Univ Med Cent). 2016 Jul;29(3):313-4
pubmed: 27365883
Cancer Immunol Immunother. 2013 Jan;62(1):125-35
pubmed: 22847020
Nature. 2018 Sep;561(7723):319-320
pubmed: 30224728
Mol Neurobiol. 2018 Apr;55(4):3211-3223
pubmed: 28478507
Int J Clin Oncol. 2016 Jun;21(3):462-73
pubmed: 26899259
Neuro Oncol. 2015 Jun;17(6):769-70
pubmed: 25754090
Onco Targets Ther. 2013 Nov 29;6:1737-49
pubmed: 24348050
Oncogene. 2019 Jun;38(23):4467-4479
pubmed: 30755732
Curr Proteomics. 2013 Sep;10(3):246-260
pubmed: 24228024
Oncotarget. 2017 Jan 24;8(4):7157-7174
pubmed: 27756892
Front Immunol. 2014 Apr 15;5:174
pubmed: 24782871
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Neuro Oncol. 2020 Apr 15;22(4):539-549
pubmed: 31755915
Cancers (Basel). 2019 Feb 05;11(2):
pubmed: 30764570
J Hematol Oncol. 2021 Jun 12;14(1):92
pubmed: 34118979
Exp Cell Res. 2013 Mar 10;319(5):731-9
pubmed: 23211717
Nat Rev Cancer. 2006 Jan;6(1):24-37
pubmed: 16397525
Int J Cancer. 2013 Feb 15;132(4):843-53
pubmed: 22752934
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Lancet Oncol. 2011 Oct;12(11):997-1003
pubmed: 21868284
Nat Immunol. 2018 Jul;19(7):696-707
pubmed: 29925992
Cancer Lett. 2021 Oct 1;517:35-45
pubmed: 34098063
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
J Neurooncol. 2019 Jun;143(2):241-249
pubmed: 31025274
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385717
Cell Death Dis. 2016 Oct 27;7(10):e2434
pubmed: 27787518
Cancer Manag Res. 2019 Aug 02;11:7307-7315
pubmed: 31447588
Front Immunol. 2021 May 07;12:637146
pubmed: 34025646
Cancer Immunol Res. 2019 Dec;7(12):1928-1943
pubmed: 31530559
Oncotarget. 2018 Apr 17;9(29):20681-20697
pubmed: 29755681
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Front Immunol. 2020 Jun 18;11:1191
pubmed: 32625208
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
Nat Commun. 2019 Aug 28;10(1):3850
pubmed: 31462642
Anticancer Res. 2018 Sep;38(9):5049-5056
pubmed: 30194149
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Onco Targets Ther. 2021 Mar 08;14:1771-1782
pubmed: 33727827
Nat Neurosci. 2012 Jul 26;15(8):1096-101
pubmed: 22837040
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119
J Neurol. 2018 Apr;265(4):741-756
pubmed: 29209782
Front Oncol. 2018 Oct 23;8:464
pubmed: 30406030
Future Oncol. 2015;11(3):511-24
pubmed: 25241806